Last reviewed · How we verify
Ozurdex intravitreal injection
Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly into the vitreous to suppress inflammation and reduce macular edema.
Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly into the vitreous to suppress inflammation and reduce macular edema. Used for Macular edema following retinal vein occlusion, Macular edema in uveitis, Diabetic macular edema.
At a glance
| Generic name | Ozurdex intravitreal injection |
|---|---|
| Sponsor | Nune Eye Hospital, Seoul, Korea |
| Drug class | Corticosteroid implant |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The implant releases dexamethasone, a potent corticosteroid, over several months directly into the eye. This local delivery suppresses inflammatory cytokines and reduces vascular permeability, thereby decreasing macular edema and improving vision in inflammatory retinal conditions. The sustained-release formulation allows for prolonged therapeutic effect with a single intravitreal injection.
Approved indications
- Macular edema following retinal vein occlusion
- Macular edema in uveitis
- Diabetic macular edema
Common side effects
- Cataract progression
- Elevated intraocular pressure
- Conjunctival hemorrhage
- Vitreous hemorrhage
- Endophthalmitis
Key clinical trials
- Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX) (PHASE2)
- Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
- Intravitreal and Intracameral DEX in NPDR (PHASE3)
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema (PHASE1, PHASE2)
- Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection (NA)
- Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema (PHASE4)
- One Year Trial Evaluating Safety of Ozurdex With Eylea (PHASE4)
- Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ozurdex intravitreal injection CI brief — competitive landscape report
- Ozurdex intravitreal injection updates RSS · CI watch RSS
- Nune Eye Hospital, Seoul, Korea portfolio CI